IL141785A0 - A pharmaceutical composition containing an ap2 inhibitor - Google Patents

A pharmaceutical composition containing an ap2 inhibitor

Info

Publication number: IL141785A0
Authority: IL; Israel
Prior art keywords: inhibitor; pharmaceutical composition; composition containing; pravastatin; employing
Prior art date: 1998-09-17

Application number

IL14178599A

Other languages

English (en)

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2002-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL141785(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-03-10 Publication of IL141785A0 publication Critical patent/IL141785A0/xx

Links

239000003112 inhibitor Substances 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
230000000879 anti-atherosclerotic effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

IL14178599A 1998-09-17 1999-09-13 A pharmaceutical composition containing an ap2 inhibitor IL141785A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10067798P	1998-09-17	1998-09-17
PCT/US1999/021069 WO2000015230A1 (en)	1998-09-17	1999-09-13	METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (1)

Publication Number	Publication Date
IL141785A0 true IL141785A0 (en)	2002-03-10

Family

ID=22280975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14178699A IL141786A0 (en)	1998-09-17	1999-09-13	A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
IL14178599A IL141785A0 (en)	1998-09-17	1999-09-13	A pharmaceutical composition containing an ap2 inhibitor

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
IL14178699A IL141786A0 (en)	1998-09-17	1999-09-13	A pharmaceutical composition for treating diabetes containing an ap2 inhibitor

Country Status (30)

Country	Link
US (1)	US20020035064A1 (de)
EP (2)	EP1113801A4 (de)
JP (2)	JP2002524518A (de)
KR (2)	KR20010075150A (de)
CN (2)	CN1317970A (de)
AT (1)	ATE406898T1 (de)
AU (2)	AU755563B2 (de)
BG (2)	BG105431A (de)
BR (2)	BR9913831A (de)
CA (2)	CA2344300A1 (de)
CO (2)	CO5130026A1 (de)
CZ (2)	CZ2001964A3 (de)
DE (1)	DE69939481D1 (de)
EE (2)	EE04356B1 (de)
ES (1)	ES2311306T3 (de)
GE (2)	GEP20033045B (de)
HU (2)	HUP0104108A2 (de)
ID (2)	ID27833A (de)
IL (2)	IL141786A0 (de)
LT (2)	LT4871B (de)
LV (2)	LV12686B (de)
NO (2)	NO20011352L (de)
NZ (2)	NZ510207A (de)
PE (2)	PE20001056A1 (de)
PL (2)	PL346661A1 (de)
SK (1)	SK3202001A3 (de)
TR (2)	TR200100773T2 (de)
UY (2)	UY25713A1 (de)
WO (2)	WO2000015229A1 (de)
ZA (2)	ZA200207433B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2311125C (en) *	1997-11-19	2011-01-18	Takeda Chemical Industries, Ltd.	Apoptosis inhibitor
AU781295B2 (en) *	1999-02-12	2005-05-12	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
AU2005201289B2 (en) *	1999-02-12	2008-04-17	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
CA2396596A1 (en)	2000-01-28	2001-08-02	Bristol-Myers Squibb Company	Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6670380B2 (en)	2000-11-20	2003-12-30	Bristol-Myers Squibb Co.	Pyridone inhibitors of fatty acid binding protein and method
AU2002254940A1 (en) *	2001-03-12	2002-09-24	Novartis Pharma Gmbh	Combination of nateglinide or repaglinide with at least one further antidiabetic compound
WO2003006023A1 (en)	2001-07-13	2003-01-23	Bristol-Myers Squibb Company	Pyrazinone inhibitors of fatty acid binding protein and method
WO2003007888A2 (en) *	2001-07-20	2003-01-30	Adipogenix, Inc.	Fat accumulation-modulating compounds
EP1443919A4 (de)	2001-11-16	2006-03-22	Bristol Myers Squibb Co	Doppelte hemmer des adipozyten-fettsäure-bindungsproteins und des keratinozyten-fettsäure-bindungsproteins
US7572922B2 (en)	2003-01-27	2009-08-11	Merck & Co., Inc.	Substituted pyrazoles, compositions containing such compounds and methods of use
US20070043512A1 (en) *	2003-03-26	2007-02-22	Michael Rolph	Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) *	2003-04-30	2004-11-11	Pfizer Products Inc.	Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
US7932268B2 (en)	2004-03-05	2011-04-26	The Trustees Of The University Of Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
DE602005006806D1 (de)	2004-06-04	2008-06-26	Merck & Co Inc	Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1841749A1 (de)	2004-09-02	2007-10-10	Metabasis Therapeutics, Inc.	Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
NZ560712A (en)	2005-02-17	2010-12-24	Synta Pharmaceuticals Corp	(3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
JP2009502923A (ja)	2005-07-26	2009-01-29	メルクエンドカムパニーインコーポレーテッド	置換ピラゾールを合成するための方法
EP1951220A2 (de) *	2005-10-18	2008-08-06	Aegerion Pharmaceuticals	Zusammensetzungen zur senkung der serumcholesterin- und/oder triglyceridwerte
CA2654183A1 (en) *	2006-06-02	2007-12-13	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
CA2673290A1 (en) *	2006-12-21	2008-07-03	Aegerion Pharmaceuticals, Inc.	Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
EP2358716B1 (de) *	2008-11-12	2016-01-06	Merck Sharp & Dohme Corp.	Inhibitoren des fettsäurebindenden proteins (fatty acid binding protein, fabp)
CN107141353A (zh) *	2009-03-05	2017-09-08	哈佛学院董事会	分泌的aP2及其抑制方法
JP6223376B2 (ja) *	2014-03-24	2017-11-01	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6514282B2 (ja) *	2014-03-24	2019-05-15	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
EP3288584A2 (de)	2015-04-30	2018-03-07	President and Fellows of Harvard College	Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
BR112018076703A2 (pt) *	2016-06-27	2019-04-02	President And Fellows Of Harvard College	compostos úteis para tratar distúrbios metabólicos
CA3066733A1 (en)	2017-06-09	2018-12-13	President And Fellows Of Harvard College	Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
JP2023532888A (ja)	2020-06-27	2023-08-01	クレセンタバイオサイエンシズ	細胞代謝を調節する化合物の組成及び使用方法
US20230285376A1 (en)	2020-07-29	2023-09-14	Amryt Pharmaceuticals Inc.	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2129012A1 (de)	1971-06-11	1973-01-04	Merck Patent Gmbh	Azol-derivate
FR2156486A1 (en)	1971-10-22	1973-06-01	Roussel Uclaf	Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (de)	1974-06-07	1981-03-18
GB1507032A (en)	1974-08-06	1978-04-12	Serono Lab	2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
FI89493C (fi)	1987-05-22	1993-10-11	Squibb & Sons Inc	Foerfarande foer framstaellning av terapeutiskt aktiva, fosforhaltiga inhibitorer av hmg-coa-reduktas och vid foerfarandet anvaendbar ny mellanprodukt
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) *	1989-10-27	1993-06-08	American Home Products Corporation	Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) *	1989-10-27	1991-09-13	American Home Prod	Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) *	1989-12-20	1993-11-16	Bristol-Myers Squibb Company	[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr)	1990-06-14	1994-05-06	Bellon Laboratoires	Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5187188A (en) *	1992-04-03	1993-02-16	Bristol-Myers Squibb Company	Oxazole carboxylic acid derivatives
US5348969A (en) *	1992-04-03	1994-09-20	Bristol-Myers Squibb Company	Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5254576A (en) *	1992-04-03	1993-10-19	Bristol-Myers Squibb Company	Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5362879A (en) *	1993-04-15	1994-11-08	Bristol-Myers Squibb Company	4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de)	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
CA2179399A1 (en) *	1993-12-20	1995-06-29	Kiyoshi Taniguchi	4,5-diaryloxazole derivatives
US5599770A (en)	1994-07-15	1997-02-04	Kureha Kagaku Kogyo Kabushiki Kaisha	Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
WO1996004261A1 (en)	1994-07-29	1996-02-15	Smithkline Beecham Plc	Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk)	1995-05-08	2003-06-16	Фармація Енд Апджон Компані	<font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en)	1996-01-05	1996-03-06	Foster Wheeler Petrol Dev Ltd	Spacing bouy for flexible risers
AUPO134596A0 (en)	1996-08-01	1996-08-22	Jal Pastoral Co. Pty Ltd	Demountable article carrier for motor vehicles
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

1999
- 1999-09-13 TR TR2001/00773T patent/TR200100773T2/xx unknown
- 1999-09-13 HU HU0104108A patent/HUP0104108A2/hu unknown
- 1999-09-13 JP JP2000569814A patent/JP2002524518A/ja active Pending
- 1999-09-13 CZ CZ2001964A patent/CZ2001964A3/cs unknown
- 1999-09-13 ES ES99951438T patent/ES2311306T3/es not_active Expired - Lifetime
- 1999-09-13 NZ NZ510207A patent/NZ510207A/en unknown
- 1999-09-13 PL PL99346661A patent/PL346661A1/xx unknown
- 1999-09-13 NZ NZ510209A patent/NZ510209A/en unknown
- 1999-09-13 CZ CZ2001965A patent/CZ2001965A3/cs unknown
- 1999-09-13 WO PCT/US1999/020946 patent/WO2000015229A1/en not_active Ceased
- 1999-09-13 SK SK320-2001A patent/SK3202001A3/sk unknown
- 1999-09-13 CA CA002344300A patent/CA2344300A1/en not_active Abandoned
- 1999-09-13 CN CN99811000A patent/CN1317970A/zh active Pending
- 1999-09-13 EE EEP200100154A patent/EE04356B1/xx not_active IP Right Cessation
- 1999-09-13 HU HU0104240A patent/HUP0104240A2/hu unknown
- 1999-09-13 GE GEAP19995860A patent/GEP20033045B/en unknown
- 1999-09-13 JP JP2000569813A patent/JP2002524517A/ja active Pending
- 1999-09-13 ID IDW20010626A patent/ID27833A/id unknown
- 1999-09-13 WO PCT/US1999/021069 patent/WO2000015230A1/en not_active Ceased
- 1999-09-13 CN CN99811096A patent/CN1319012A/zh active Pending
- 1999-09-13 BR BR9913831-0A patent/BR9913831A/pt not_active IP Right Cessation
- 1999-09-13 TR TR2001/00774T patent/TR200100774T2/xx unknown
- 1999-09-13 PL PL99346660A patent/PL346660A1/xx not_active Application Discontinuation
- 1999-09-13 IL IL14178699A patent/IL141786A0/xx unknown
- 1999-09-13 GE GEAP19995861A patent/GEP20033044B/en unknown
- 1999-09-13 CA CA002344309A patent/CA2344309A1/en not_active Abandoned
- 1999-09-13 EP EP99948210A patent/EP1113801A4/de not_active Withdrawn
- 1999-09-13 KR KR1020017003411A patent/KR20010075150A/ko not_active Withdrawn
- 1999-09-13 AU AU61437/99A patent/AU755563B2/en not_active Ceased
- 1999-09-13 AT AT99951438T patent/ATE406898T1/de not_active IP Right Cessation
- 1999-09-13 EE EEP200100155A patent/EE200100155A/xx unknown
- 1999-09-13 BR BR9913833-6A patent/BR9913833A/pt not_active IP Right Cessation
- 1999-09-13 AU AU63877/99A patent/AU754488B2/en not_active Ceased
- 1999-09-13 KR KR1020017003408A patent/KR20010079842A/ko not_active Withdrawn
- 1999-09-13 IL IL14178599A patent/IL141785A0/xx unknown
- 1999-09-13 DE DE69939481T patent/DE69939481D1/de not_active Revoked
- 1999-09-13 EP EP99951438A patent/EP1121129B1/de not_active Revoked
- 1999-09-13 ID IDW20010624A patent/ID28450A/id unknown
- 1999-09-15 CO CO99058376A patent/CO5130026A1/es unknown
- 1999-09-15 CO CO99058374A patent/CO5130025A1/es unknown
- 1999-09-16 UY UY25713A patent/UY25713A1/es unknown
- 1999-09-16 UY UY25714A patent/UY25714A1/es unknown
- 1999-09-17 PE PE1999000943A patent/PE20001056A1/es not_active Application Discontinuation
- 1999-09-17 PE PE1999000944A patent/PE20001047A1/es not_active Application Discontinuation
2001
- 2001-03-16 NO NO20011352A patent/NO20011352L/no not_active Application Discontinuation
- 2001-03-16 LT LT2001022A patent/LT4871B/lt not_active IP Right Cessation
- 2001-03-16 NO NO20011351A patent/NO20011351L/no unknown
- 2001-03-16 LT LT2001023A patent/LT4870B/lt not_active IP Right Cessation
- 2001-04-10 BG BG105431A patent/BG105431A/xx unknown
- 2001-04-10 BG BG105432A patent/BG105432A/xx unknown
- 2001-04-12 LV LV010057A patent/LV12686B/xx unknown
- 2001-04-12 LV LV010058A patent/LV12687B/xx unknown
- 2001-07-13 US US09/905,235 patent/US20020035064A1/en not_active Abandoned
2002
- 2002-09-16 ZA ZA200207433A patent/ZA200207433B/en unknown
- 2002-09-16 ZA ZA200207430A patent/ZA200207430B/en unknown

Also Published As

Publication number	Publication date
CO5130025A1 (es)	2002-02-27
GEP20033044B (en)	2003-08-25
KR20010075150A (ko)	2001-08-09
UY25714A1 (es)	2001-08-27
NO20011352D0 (no)	2001-03-16
CZ2001965A3 (cs)	2002-02-13
LT2001023A (en)	2001-08-27
BR9913833A (pt)	2001-05-29
BG105432A (en)	2001-12-29
EP1121129B1 (de)	2008-09-03
CO5130026A1 (es)	2002-02-27
PE20001047A1 (es)	2000-12-24
AU6143799A (en)	2000-04-03
NZ510207A (en)	2003-08-29
CN1317970A (zh)	2001-10-17
EE200100155A (et)	2002-08-15
NO20011351D0 (no)	2001-03-16
PL346660A1 (en)	2002-02-25
ZA200207433B (en)	2003-10-27
LT4870B (lt)	2001-12-27
US20020035064A1 (en)	2002-03-21
CZ2001964A3 (cs)	2002-01-16
SK3202001A3 (en)	2002-04-04
NZ510209A (en)	2003-07-25
CA2344309A1 (en)	2000-03-23
JP2002524518A (ja)	2002-08-06
GEP20033045B (en)	2003-08-25
TR200100774T2 (tr)	2001-12-21
EP1113801A1 (de)	2001-07-11
KR20010079842A (ko)	2001-08-22
ID27833A (id)	2001-04-26
LT2001022A (en)	2001-08-27
EP1113801A4 (de)	2002-10-02
PE20001056A1 (es)	2000-12-24
NO20011351L (no)	2001-05-11
CA2344300A1 (en)	2000-03-23
EP1121129A1 (de)	2001-08-08
JP2002524517A (ja)	2002-08-06
ID28450A (id)	2001-05-24
UY25713A1 (es)	2001-08-27
HUP0104108A2 (hu)	2002-03-28
EE04356B1 (et)	2004-10-15
BG105431A (en)	2001-12-29
PL346661A1 (en)	2002-02-25
EP1121129A4 (de)	2002-10-16
AU6387799A (en)	2000-04-03
ES2311306T3 (es)	2009-02-01
EE200100154A (et)	2002-12-16
CN1319012A (zh)	2001-10-24
BR9913831A (pt)	2001-05-29
IL141786A0 (en)	2002-03-10
HUP0104240A2 (hu)	2002-03-28
WO2000015230A1 (en)	2000-03-23
ATE406898T1 (de)	2008-09-15
LT4871B (lt)	2001-12-27
LV12686B (lv)	2001-10-20
LV12686A (en)	2001-07-20
TR200100773T2 (tr)	2001-07-23
NO20011352L (no)	2001-05-11
DE69939481D1 (de)	2008-10-16
ZA200207430B (en)	2003-09-16
AU755563B2 (en)	2002-12-12
AU754488B2 (en)	2002-11-14
WO2000015229A1 (en)	2000-03-23
LV12687A (en)	2001-07-20
LV12687B (lv)	2001-10-20

Publication	Publication Date	Title
IL141785A0 (en)	2002-03-10	A pharmaceutical composition containing an ap2 inhibitor
WO1996009827A3 (en)	1996-05-23	Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
BR9714364A (pt)	2000-03-21	Amidas inibidoras da secreção de apo b/mtp
AU1022795A (en)	1995-07-27	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
NO872259D0 (no)	1987-05-29	Fremgangsmaate for fremstilling av terapeutisk aktive trans-6(2-(3-eller 4-karboksamido-substituert pyrrol-1-yl)alkyl)-4-hydroksypyran-2-on-derivater.
AU688952B2 (en)	1998-03-19	Thrombin inhibitors
HUP0103007A3 (en)	2003-10-28	New salts of hmg-coa reductase inhibitors and process for their preparation
YU29601A (sh)	2003-04-30	Novi estri izvedeni iz supstituisanih fenil-cikloheksil jedinjenja
GEP20053548B (en)	2005-06-27	Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
BR9811099A (pt)	2002-05-14	Inibidores de urocinase
PL331339A1 (en)	1999-07-05	Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase
AU3366297A (en)	1998-01-14	Polymorphic compounds
MY118381A (en)	2004-10-30	Statin-carboxyalkylether combinations
CY2216B1 (en)	2003-04-18	Enzymatic hydroxylation process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
MY140504A (en)	2009-12-31	Statin-mmp inhibitor combinations
BR0112460A (pt)	2003-07-22	Método para tratamento de sépsis
AU2177701A (en)	2001-06-12	Use of hmg-coa reductase inhibitors for treating seborrhea
ZA985179B (en)	1999-01-08	Process for producing medicaments which comprise HMG CoA reductase inhibitors
IT1255470B (it)	1995-11-02	Composti attivi come inibitori dell'enzima hmg-coa reduttasi
MX9602577A (es)	1998-01-31	Tratamiento de arterioesclerosis y xantoma.